INT124651

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.30
First Reported 2005
Last Reported 2007
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 5
Disease Relevance 0.64
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleoplasm (XPO1) nuclear envelope (XPO1) cytoplasm (XPO1)
cytosol (XPO1) protein transporter activity (XPO1) RNA binding (XPO1)
Anatomy Link Frequency
fat 1
XPO1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Paracetamol 4 50.00 Quite Low
Inflammation 32 5.00 Very Low Very Low Very Low
tolerance 4 5.00 Very Low Very Low Very Low
Pain 4 5.00 Very Low Very Low Very Low
alcohol 4 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Frailty 20 98.84 Very High Very High Very High
Aging 28 94.52 High High
Nephrotoxicity 1 68.48 Quite High
Metastasis 4 66.44 Quite High
Death 1 50.00 Quite Low
Endometriosis (extended) 4 43.76 Quite Low
Nicotine Addiction 4 42.32 Quite Low
Renal Failure 4 40.64 Quite Low
Diabetes Mellitus 20 40.04 Quite Low
Pulmonary Disease 4 39.28 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Creatine monohydrate (CrM) is a guanidino compound that is produced endogenously and is naturally occurring in meat containing products.
Gene_expression (produced) of CrM
1) Confidence 0.30 Published 2007 Journal PLoS ONE Section Body Doc Link PMC1994592 Disease Relevance 0.44 Pain Relevance 0
After completion of pre-training testing, subjects were then randomized to either a combination of CrM and CLA (CrM+CLA) (5 g CrM (Neotine®)+2 g dextrose/d, Palo Alta, CA); and 6 g of CLA (CLA-ONE® 45% c9, t11; 45% t10, c12, Pharmanutrients, Gurnee, IL) or placebo (PL) (7 g dextrose/d+6 g of safflower oil/d) for 24 weeks.
Gene_expression (combination) of CrM
2) Confidence 0.26 Published 2007 Journal PLoS ONE Section Body Doc Link PMC1994592 Disease Relevance 0.07 Pain Relevance 0
After completion of pre-training testing, subjects were then randomized to either a combination of CrM and CLA (CrM+CLA) (5 g CrM (Neotine®)+2 g dextrose/d, Palo Alta, CA); and 6 g of CLA (CLA-ONE® 45% c9, t11; 45% t10, c12, Pharmanutrients, Gurnee, IL) or placebo (PL) (7 g dextrose/d+6 g of safflower oil/d) for 24 weeks.
Gene_expression (combination) of CrM
3) Confidence 0.26 Published 2007 Journal PLoS ONE Section Body Doc Link PMC1994592 Disease Relevance 0.07 Pain Relevance 0
There was a significantly greater reduction in fat mass in the CrM+CLA group following training (?
Gene_expression (group) of CrM in fat
4) Confidence 0.23 Published 2007 Journal PLoS ONE Section Body Doc Link PMC1994592 Disease Relevance 0 Pain Relevance 0
The constitutive expression of the viral caspase inhibitor CrmA decreased the rate of apoptosis by 60% at 24 hours and the broad-specific caspase inhibitor zVAD-fmk prevented paracetamol-induced features of apoptosis.
Gene_expression (expression) of CrmA
5) Confidence 0.00 Published 2005 Journal Kidney Int. Section Body Doc Link 15673306 Disease Relevance 0.07 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox